Physician profile
Nasser E Borai
NPI 1427031681
$12,628.72
in general payments reported to CMS, 2019-2025
39 companies · $4,041 in 2025
The $4,041 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $565 · 2021: $339 · 2022: $6,128 · 2023: $554 · 2024: $585 · 2025: $4,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $1,484 · Travel and Lodging: $1,083 · Education: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $1,483.75 |
| Travel and Lodging | $1,083.46 |
| Education | $613.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,717.24 | 2020-2025 | Jakafi |
| Avyxa Pharma, LLC | $3,552.61 | 2025 | |
| Glaxosmithkline, LLC. | $1,671.43 | 2022-2025 | Ojjaara, Jemperli |
| Astellas Pharma US INC | $354.83 | 2020-2023 | Padcev |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Seagen INC. | $238.39 | 2019-2023 | Padcev |
| Janssen Pharmaceuticals, INC | $188.63 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $172.41 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $165.53 | 2019-2023 | |
| Asd Specialty Healthcare, LLC | $161.90 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $124.71 | 2019-2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $94.36 | 2019-2022 | |
| Pfizer INC. | $78.09 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.19 | 2019-2024 | |
| Array Biopharma INC | $73.19 | 2024-2025 | Braftovi, Mektovi, Tukysa |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $64.33 | 2019-2020 | |
| Celgene Corporation | $63.32 | 2022-2025 | Reblozyl |
| Gilead Sciences, INC. | $63.29 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $55.79 | 2020-2024 | Keytruda, Lenvima |
| Abbvie INC. | $40.03 | 2019-2022 | |
| Janssen Biotech, INC. | $39.91 | 2019-2024 | Erleada, Balversa, Akeega |
| Lilly USA, LLC | $28.94 | 2019 | |
| Exelixis INC. | $27.19 | 2023-2024 | Cabometyx |
| Mirati Therapeutics, INC. | $18.76 | 2023 | Krazati |
| Tempus Ai, INC | $18.17 | 2024 | Xt Cdx |
| Springworks Therapeutics, INC. | $16.22 | 2025 | Ogsiveo |
| Aveo Pharmaceuticals, INC. | $15.46 | 2024 | |
| Amgen INC. | $14.41 | 2022 | |
| Eisai INC. | $14.24 | 2019 | |
| Daiichi Sankyo INC. | $14.24 | 2019 | |
| Taiho Oncology, INC. | $14.14 | 2019 | |
| Sirtex Medical INC | $13.85 | 2019 | |
| Genzyme Corporation | $13.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.80 | 2019 | |
| Coherus Oncology, INC. | $13.16 | 2022 | |
| Rigel Pharmaceuticals, INC. | $12.66 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.60 | 2020 | |
| Tesaro, INC. | $11.96 | 2019 | |
| Epizyme, INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasser Borai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.